http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101969773-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-716 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23G3-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23G3-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23G3-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23G3-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C61-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23G3-563 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-90 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C53-132 |
| filingDate | 2009-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-101969773-B |
| titleOfInvention | Compounds and methods for lowering uric acid |
| abstract | Uric acid is reduced and uric acid excretion is increased in a mammalian subject by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), m is 0, 1, 2, 3 or 4; n is 0 or 1; m+n is not more than 4; t is 0 or 1; q is 0 or 1; r is 0, 1 or 2 . R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxyl and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are -CH2CH2- . R 7 is hydrogen or an alkyl group having 1 to 3 carbon atoms. One of R 8 and R 9 is an alkyl group having 1 to 3 carbon atoms, and the other is hydrogen or an alkyl group having 1 to 3 carbon atoms. R 10 is hydrogen, halogen, alkyl having 1 to 3 carbon atoms or alkoxy having 1 to 3 carbon atoms. X is C(O), r is 0, and t is 0; or X is NH(R 11 ), wherein R 11 is hydrogen or an alkyl group having 1 to 3 carbon atoms. A is a phenyl group with no substituent or a phenyl group with 1 or 2 groups selected from the following groups as substituents: halogen, hydroxyl, methyl, ethyl, perfluoromethyl, methyl Oxy, ethoxy, and perfluoromethoxy; or A is a five- or six-membered heteroaryl ring having 1 or 2 ring heteroatoms selected from N, S, and O, said heteroaryl ring passing through the ring carbon Covalently linked to the rest of the compound of formula I; or A is a cycloalkyl group having 3 to 6 ring carbon atoms, wherein the cycloalkyl group has no substituent or one or two ring carbons are independently methylated or ethyl monosubstituted. The compound of formula (I) having the effect of lowering uric acid is used to treat or prevent various diseases, including gout, hyperuricemia, an increase in the level of uric acid that does not meet the level of diagnosis of hyperuricemia, renal dysfunction, Kidney stones, cardiovascular disease, risk of developing cardiovascular disease, and cognitive impairment. Described formula (I) is: |
| priorityDate | 2008-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.